Why in News?
The unavailability of essential drugs for treating Sickle Cell Disease (SCD) at district healthcare institutions has highlighted the systemic challenges faced by marginalised Indigenous Tribal communities in accessing timely and effective treatment.
What is Sickle Cell Disease?
Sickle Cell Disease (SCD) is an inherited haemoglobin disorder caused by a genetic mutation that alters the structure of red blood cells.
- Normal RBCs are round and flexible
- In SCD, RBCs become sickle or crescent-shaped, rigid, and sticky
- These abnormal cells obstruct blood flow, impair oxygen delivery, and break down prematurely
As a result, SCD leads to chronic anaemia, recurrent pain crises, organ damage, increased infection risk, and reduced life expectancy.
According to the Ministry of Health and Family Welfare, tribal and marginalised populations are the most vulnerable.
Symptoms of SCD
- Chronic anaemia causing fatigue, weakness, and pallor
- Painful vaso-occlusive crises, often severe and recurrent
- Delayed growth and puberty in children
- Increased susceptibility to infections
- Progressive organ damage affecting the spleen, kidneys, lungs, and brain
Treatment Options
SCD has no universal cure, but long-term management reduces complications.
Conventional Treatments
- Blood transfusions to manage anaemia and reduce pain crises
- Hydroxyurea, which increases fetal haemoglobin and reduces pain episodes and complications
Advanced Therapies
- Bone marrow / stem cell transplantation (curative but donor-dependent)
- Gene therapy, including CRISPR-based approaches
However, advanced treatments remain prohibitively expensive (USD 2–3 million) and limited by donor availability and infrastructure.
India’s Current Status of SCD
- India ranks third globally in SCD births, after Nigeria and the Democratic Republic of the Congo
- 15,000–25,000 babies with SCD are born annually
- The disease is concentrated in tribal regions, reflecting deep geographical and socioeconomic inequities
Key Challenges in Treatment and Accessibility
Limited Awareness
- Low public and healthcare worker awareness
- Delayed diagnosis and inadequate genetic counselling
Inadequate Healthcare Infrastructure
- Lack of specialised facilities and trained personnel in tribal and rural areas
High Cost of Treatment
- Long-term care involves repeated hospital visits and expensive medications
- Gene therapies remain inaccessible to most patients
Limited Access to Medicines
- Inconsistent availability of hydroxyurea and pain management drugs
Weak Screening Mechanisms
- Absence of universal newborn screening and carrier detection
Geographical and Social Barriers
- Remote habitation, poor transport, poverty
- Stigma and discrimination worsen exclusion from healthcare services
Government Initiatives on SCD
National Sickle Cell Anaemia Elimination Mission
- Aims to eliminate SCD as a public health problem by 2047
- Focus on screening, awareness, counselling, and care delivery
- CSIR developing gene-editing therapies under the mission
National Health Mission (NHM), 2013
- Addresses hereditary disorders including SCD
- Supports awareness, early diagnosis, and treatment
- Includes hydroxyurea in the Essential Medicines List
National Guidelines for Stem Cell Research, 2017
- Permits bone marrow transplantation for SCD
- Restricts commercial stem cell therapies
- Gene editing allowed only for in-vitro research
National Guidelines for Gene Therapy Product Development, 2019
- Framework for clinical trials of gene therapies for inherited disorders
- India approved a five-year CRISPR research project for SCD
State-level Initiatives
- Madhya Pradesh Haemoglobinopathy Mission focuses on screening and disease management
Rights of Persons with Disabilities Act, 2016
- SCD included among 21 recognised disabilities
- Benefits include:
- Minimum 5% reservation in higher education
- Minimum 4% reservation in government jobs
- Free education for children (6–18 years) with benchmark disability
International Developments
- US FDA approved Lyfgenia and Casgevy for SCD
- Casgevy is the first CRISPR-based therapy to receive regulatory approval (also approved in the UK)
- Lyfgenia uses viral vectors instead of CRISPR
Both therapies involve:
- Extraction of patient’s blood stem cells
- Genetic modification
- High-dose chemotherapy
- Re-infusion via hematopoietic stem cell transplantation
Way Forward
Early Detection and Screening
- Universal newborn screening in high-prevalence regions
- Early identification of carriers with genetic counselling
Affordable Treatment Access
- Ensure uninterrupted availability of hydroxyurea
- Strengthen district-level healthcare capacity
Awareness and Community Engagement
- Targeted awareness programmes in tribal regions
- Education on hereditary nature and stigma reduction
- Public participation in regulatory decision-making
Research and Innovation
- Invest in cost-effective gene therapies
- Promote equitable access to clinical trials
Health Equity Focus
- Integrate SCD care with primary healthcare systems
- Address social determinants affecting tribal health outcomes
